Skip to content

Jazz Pharmaceuticals JAZZ Income Statement

FY'25FY'24FY'23FY'22
$4.27B+4.9%$4.07B+6.1%$3.83B+4.8%$3.66B+18.3%
$1.81B+30.6%$1.39B+3.1%$1.34B-5.2%$1.42B-2.4%
$4.7B+40.1%$3.35B+3.0%$3.26B-12.6%$3.72B+27.4%
$716.63M+23.9%$578.58M+983%-$65.53M-138%
$248.56M-21.0%$314.82M-5.5%$333.11M+23.1%$270.67M+95.8%
-$17.98M+42.6%-$31.31M
$470.35M+57.9%$297.93M+180%-$372.78M-230%
-$277.39M-203%-$91.43M+23.8%-$119.91M+24.4%-$158.65M-169%
$560.12M+35.0%$414.83M+285%-$224.06M+32.0%
$8.70+41.9%$6.13+272%-$3.57+34.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Jazz Pharmaceuticals's revenue?
Jazz Pharmaceuticals (JAZZ) generated $4.4B in revenue over the trailing twelve months, up 9.2% year over year.
Is Jazz Pharmaceuticals profitable?
Jazz Pharmaceuticals is not currently profitable: it reported a net loss of $266.5M over the trailing twelve months, a -8.9% net margin.
What is Jazz Pharmaceuticals's earnings per share?
Jazz Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.75.
Where does Jazz Pharmaceuticals's income statement data come from?
Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.